| Enzalutamide |
EU/1/13/846/001 |
Xtandi, Capsule, soft, 40, mg, Pack: 112 |
Astellas Pharma Europe B.V., Нидерландия |
Astellas Pharma Europe B.V., Нидерландия |
5957.69 |
1191.54 |
7149.23 |
4% |
10 |
5967.69 |
1193.54 |
7161.23 |
16% |
25 |
5992.69 |
1198.54 |
7191.23 |
|
НСР-4884/17.10.2014 |
03.11.2014 |
03.11.2014 |
Неактивен |
3277 |
| insulin degludec, liraglutide |
EU/1/14/947/002 |
Xultophy, Solution for injection, 100U/ml/3.6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk A/S - Дания |
218.66 |
43.73 |
262.39 |
4% |
8.75 |
227.41 |
45.48 |
272.89 |
16% |
25 |
252.41 |
50.48 |
302.89 |
|
НСР-14730/21.12.2017 предварително изпълнение; НСР-17864/07.02.2019 |
22.02.2019 |
02.03.2019 |
Активен |
15955 |
| insulin degludec, liraglutide |
EU/1/14/947/002 |
Xultophy, Solution for injection, 100U/ml/3.6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk A/S - Дания |
230.83 |
46.17 |
277 |
4% |
9.23 |
240.06 |
48.01 |
288.07 |
16% |
25 |
265.06 |
53.01 |
318.07 |
|
НСР-14730/21.12.2017 предварително изпълнение |
21.12.2017 |
02.01.2018 |
Неактивен |
15955 |
| Levocetirizine |
20060437 |
Xyzal, Oral drops, solution, 5 mg/ml - 20 ml, mg, Pack: 1 |
UCB Pharma GmbH, Германия |
UCB Pharma S.p.A., Italy |
7.31 |
1.46 |
8.77 |
7% |
0.51 |
7.82 |
1.56 |
9.38 |
20% |
1.46 |
9.28 |
1.86 |
11.14 |
промяна на обстоятелства НСР-6252/21.05.2015 ; корекц. Решение НСР-6584/01.07.2015 |
НСР-1607/01.11.2013; НСР-19114/04.07.2019 |
19.07.2019 |
02.08.2019 |
Активен |
2228 |
| Levocetirizine |
20060437 |
Xyzal, Oral drops, solution, 5 mg/ml - 20 ml, mg, Pack: 1 |
UCB Pharma GmbH, Германия |
UCB Pharma S.p.A., Italy |
7.39 |
1.48 |
8.87 |
7% |
0.52 |
7.91 |
1.58 |
9.49 |
20% |
1.48 |
9.39 |
1.88 |
11.27 |
промяна на обстоятелства НСР-6252/21.05.2015 ; корекц. Решение НСР-6584/01.07.2015 |
НСР-1607/01.11.2013 |
18.11.2013 |
18.11.2013 |
Неактивен |
2228 |
| Levocetirizine |
II-14118/ 15.01.2006 |
Xyzal, Oral drops, solution, 5 mg/ml - 20 ml, mg, Pack: 1 |
UCB GmbH, Германия |
UCB Pharma S.p.A., Italy |
8.76 |
1.75 |
10.51 |
7% |
0.61 |
9.37 |
1.87 |
11.24 |
20% |
1.75 |
11.12 |
2.22 |
13.34 |
|
КЦРР-1097/26.07.2012 |
17.08.2012 |
17.08.2012 |
Неактивен |
2228 |
| Levocetirizine |
II-14118/15.01.2006 |
Xyzal, Oral drops, solution, 5 mg/ml - 20 ml, mg, Pack: 1 |
UCB GmbH, Германия |
UCB Pharma S.p.A., Italy |
9.99 |
2 |
11.99 |
9% |
0.9 |
10.89 |
2.18 |
13.07 |
22% |
2.2 |
13.09 |
2.62 |
15.71 |
|
КЦ-520/09.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
2228 |
| Donepezil |
20070119 |
YASNAL, Film coated tablet, 10, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia; TAD Pharma GmbH, Германия |
11.89 |
2.38 |
14.27 |
6% |
0.71 |
12.6 |
2.52 |
15.12 |
18% |
2.14 |
14.74 |
2.95 |
17.69 |
промяна на обстоятелства и цената е вписана в регистъра на пределните цени с решение НСР-8304/26.02.2016 година (в сила от 02.04.2016 година) |
КЦРР-2424/22.02.2013 |
01.04.2013 |
01.04.2013 |
Заличен |
1724 |
| Donepezil |
20070118 |
YASNAL, Film coated tablet, 5, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia; TAD Pharma GmbH, Германия |
7.92 |
1.58 |
9.5 |
7% |
0.55 |
8.47 |
1.69 |
10.16 |
20% |
1.58 |
10.05 |
2.01 |
12.06 |
промяна на обстоятелства и вписва цената в регистъра на пределните цени с решение НСР-8303/26.02.2016 година (в сила от 02.04.2016 година) |
КЦРР-2424/22.02.2013 |
01.04.2013 |
01.04.2013 |
Заличен |
1725 |
| Donepezil |
II-1066/21.11.2007 |
YASNAL, Film coated tablet, 10, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
103.19 |
20.64 |
123.83 |
4% |
4.13 |
107.32 |
21.46 |
128.78 |
16% |
16.51 |
123.83 |
24.77 |
148.6 |
|
КЦ-326/28.11.2008 |
30.12.2008 |
30.12.2008 |
Неактивен |
1724 |
| Donepezil |
II-1065/21.11.2007 |
YASNAL, Film coated tablet, 5, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
52.81 |
10.56 |
63.37 |
4% |
2.11 |
54.92 |
10.98 |
65.9 |
16% |
8.45 |
63.37 |
12.67 |
76.04 |
|
КЦ-326/28.11.2008 |
30.12.2008 |
30.12.2008 |
Неактивен |
1725 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22107.16 |
4421.43 |
26528.59 |
4% |
10 |
22117.16 |
4423.43 |
26540.59 |
16% |
25 |
22142.16 |
4428.43 |
26570.59 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017; НСР-17766/17.01.2019 |
01.02.2019 |
02.02.2019 |
Активен |
2252 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22107.16 |
4421.43 |
26528.59 |
4% |
10 |
22117.16 |
4423.43 |
26540.59 |
16% |
25 |
22142.16 |
4428.43 |
26570.59 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017; НСР-17766/17.01.2019 |
01.02.2019 |
02.02.2019 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22107.16 |
4421.43 |
26528.59 |
4% |
10 |
22117.16 |
4423.43 |
26540.59 |
16% |
25 |
22142.16 |
4428.43 |
26570.59 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017; НСР-17766/17.01.2019 |
01.02.2019 |
02.02.2019 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22452.93 |
4490.59 |
26943.52 |
4% |
10 |
22462.93 |
4492.59 |
26955.52 |
16% |
25 |
22487.93 |
4497.59 |
26985.52 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017 |
20.05.2017 |
02.06.2017 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
5613.23 |
1122.65 |
6735.88 |
4% |
10 |
5623.23 |
1124.65 |
6747.88 |
16% |
25 |
5648.23 |
1129.65 |
6777.88 |
|
НСР-8219/22.02.2016; НСР-12576/05.05.2017 |
20.05.2017 |
02.06.2017 |
Активен |
2253 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
5613.23 |
1122.65 |
6735.88 |
4% |
10 |
5623.23 |
1124.65 |
6747.88 |
16% |
25 |
5648.23 |
1129.65 |
6777.88 |
|
НСР-8219/22.02.2016; НСР-12576/05.05.2017 |
20.05.2017 |
02.06.2017 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
5613.23 |
1122.65 |
6735.88 |
4% |
10 |
5623.23 |
1124.65 |
6747.88 |
16% |
25 |
5648.23 |
1129.65 |
6777.88 |
|
НСР-8219/22.02.2016; НСР-12576/05.05.2017 |
20.05.2017 |
02.06.2017 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6223.82 |
1244.76 |
7468.58 |
4% |
10 |
6233.82 |
1246.76 |
7480.58 |
16% |
25 |
6258.82 |
1251.76 |
7510.58 |
|
НСР-8219/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
24895.27 |
4979.05 |
29874.32 |
4% |
10 |
24905.27 |
4981.05 |
29886.32 |
16% |
25 |
24930.27 |
4986.05 |
29916.32 |
|
НСР-8218/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6223.82 |
1244.76 |
7468.58 |
4% |
10 |
6233.82 |
1246.76 |
7480.58 |
16% |
25 |
6258.82 |
1251.76 |
7510.58 |
|
НСР-8219/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
24895.27 |
4979.05 |
29874.32 |
4% |
10 |
24905.27 |
4981.05 |
29886.32 |
16% |
25 |
24930.27 |
4986.05 |
29916.32 |
|
НСР-8218/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6845.41 |
1369.08 |
8214.49 |
4% |
10 |
6855.41 |
1371.08 |
8226.49 |
16% |
25 |
6880.41 |
1376.08 |
8256.49 |
|
НСР-1792/25.11.2013 |
10.12.2013 |
10.12.2013 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
27381.62 |
5476.32 |
32857.94 |
4% |
10 |
27391.62 |
5478.32 |
32869.94 |
16% |
25 |
27416.62 |
5483.32 |
32899.94 |
|
НСР-1792/25.11.2013 |
10.12.2013 |
10.12.2013 |
Неактивен |
2252 |
| Memantine |
20140328 |
Ymana, Film coated tablet, 10, mg, Pack: 28 |
Alkaloid – INT d.o.o., Словения |
Alkaloid-INT d.o.o., Slandrova ulica 4, 1231 Ljubljana-Crnuce, Словения |
20.75 |
4.15 |
24.9 |
6% |
1.25 |
22 |
4.4 |
26.4 |
18% |
3.74 |
25.74 |
5.15 |
30.89 |
|
НСР-8372/26.02.2016; НСР-12482/28.04.2017 |
13.05.2017 |
02.06.2017 |
Активен |
4194 |